Ras mediates cell survival by regulating tuberin

Oncogene

Volumn 27, Issue 14, 2008, Pages 2072-2083

  Freilinger, A ^a   Rosner, M ^a   Hanneder, M ^a   Hengstschlager M ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

ERK; Ras; RSK; Survival; Tuberin

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; S6 KINASE; TUBERIN;

APOPTOSIS; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVITY; FIBROBLAST; GENE FUNCTION; GENE INTERACTION; HUMAN; HUMAN CELL; ONCOGENE RAS; PRIORITY JOURNAL; UPREGULATION;

APOPTOSIS; CELL SURVIVAL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HELA CELLS; HUMANS; MAP KINASE KINASE KINASES; RAS PROTEINS; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; TUMOR SUPPRESSOR PROTEINS;

EID: 41149123234     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210844     Document Type: Article

References (40)

1. Adachi H, Igawa M, Shina H, Urakami S, Shigeno K, Hino O. (2003). Human bladder tumors with 2-hit mutations of tumor suppressor gene TSC1 and decreased expression of p27. J Urol 170: 601-604.
2. Arrebola F, Canizares J, Cubero MA, Crespo PV, Warley A, Fernandez-Segura E. (2005). Biphasic behavior of changes in elemental composition during staurosporine-induced apoptosis. Apoptosis 10: 1317-1331.
3. Astrinidis A, Henske EP. (2005). Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease. Oncogene 24: 7475-7481.
4. Ballif BA, Roux PP, Gerber SA, MacKeigan JP, Blenis J, Gygi SP. (2005). Quantitativ e phosphorylation profiling of the ERK/p90 ribosomal S6 kinase-signaling cassette and its targets, the tuberous sclerosis tumor suppressors. Proc Natl Acad Sci USA 102: 667-672.
5. Cox AD, Der CJ. (2003). The dark side of Ras: regulation of apoptosis. Oncogene 22: 8999-9006.
6. Dan HC, Sun M, Yang L, Feldman RI, Sui X-M, Ou CC et al. (2002). Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin. J Biol Chem 277: 35364-35370.
7. Danial NN, Korsmeyer SJ. (2004). Cell death: critical control points. Cell 116: 205-219.
8. Downward J. (2004). PI 3-kinase, Akt and cell survival. Sem Cell Dev Biol 15: 177-182.
9. Dufner A, Thomas G. (1999). Ribosomal S6 kinase signaling and the control of translation. Exp Cell Res 253: 100-109.
10. Franke TF, Hornik CP, Segev L, Shostak GA, Sugimoto C. (2003). PI3K/Akt and apoptosis: size matters. Oncogene 22: 8983-8998.
11. Freilinger A, Rosner M, Krupitza G, Nishino M, Lubec G, Korsmeyer SJ et al. (2006). Tuberin activates the proapoptotic molecule BAD. Oncogene 25: 6467-6479.
12. Goncharova EA, Goncharov DA, Eszterhas AW, Hunter DS, Glassberg MK, Yeung RS et al. (2002). Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM). J Biol Chem 277: 30958-30967.
13. Harada H, Andersen JS, Mann M, Terada N, Korsmeyer SJ. (2001). p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc Natl Acad Sci USA 98: 9666-9670.
14. Henry KW, Yuan X, Koszewski NJ, Onda H, Kwiatkowski DJ, Noonan DJ. (1998). Tuberous sclerosis gene 2 product modulates transcription mediated by steroid hormone receptor family members. J Biol Chem 273: 20535-20539.
15. Hornigold N, Devlin J, Davies AM, Aveyard JS, Habuchi T, Knowles MA. (1999). Mutation of the 9q34 gene TSC1 in sporadic bladder cancer. Oncogene 18: 2657-2661.
16. Inoki K, Li Y, Zhu T, Wu J, Guan K-L. (2002). TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4: 648-657.
17. Inoki K, Zhu T, Guan K-L. (2003). TSC2 mediates cellular energy response to control cell growth and survival. Cell 115: 577-590.
18. Jiang WG, Sampson J, Martin TA, Lee-Jones L, Watkins G, Douglas-Jones A et al. (2005). Tuberin and hamartin are aberrantly expressed and linked to clinical outcome in human breast cancer: the role of promoter methylation of TSC genes. Eur J Cancer 41: 1628-1636.
19. Kalejta RF, Shenk T, Beavis AJ. (1997). Use of a membrane-localized green fluorescent protein allows simultaneous identification of transfected cells and cell cycle analysis by flow cytometry. Cytometry 29: 286-291.
20. Knowles MA, Habuchi T, Kennedy W, Cuthbert-Heavens D. (2003a) . Mutation spectrum of the 9q34 tuberous sclerosis gene TSC1 in transitional cell carcinoma of the bladder. Cancer Res 63: 7652-7656.
21. Knowles MA, Hornigold N, Pitt E. (2003b). Tuberous sclerosis complex (TSC) gene involvement in sporadic tumours. Biochem Soc Transact 31: 597-602.
22. Kolb TM, Duan L, Davis MA. (2005). Tsc2 expression increases the susceptibility of renal tumor cells to apoptosis. Toxicol Sci 88: 331-339.
23. Kwiatkowski DJ. (2003). Tuberous sclerosis: from tubers to mTOR. Annals Hum Genet 67: 87-96.
24. Li Y, Corradetti MN, Inoki K, Guan K-L. (2003). TSC2: filling the GAP in the mTOR signaling pathway. Trends Biochem Sci 29: 32-38.
25. Ma L, Zhenbang C, Erdjument-Bromage H, Tempst P, Pandolfi PP. (2005). Phosphoryla tion and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 121: 179-193.
26. Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC. (2002). Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell 10: 151-162.
27. Miloloza A, Rosner M, Nellist M, Halley D, Bernaschek G, Hengstschläger M. (2000). The TSC1 gene product, hamartin, negatively regulates cell proliferation. Hum Mol Genet 9: 1721-1727.
28. Pan D, Dong J, Zhang Y, Gao X. (2004). Tuberous sclerosis complex: from Drosophila to human disease. Trends Cell Biol 14: 78-85.
29. Potter CJ, Pedraza LG, Xu T. (2002). Akt regulates growth by directly phosphorylating Tsc2. Nat Cell Biol 4: 658-665.
30. Rosner M, Hengstschläger M. (2004). Tuberin binds p27 and negatively regulates its interaction with the SCF component Skp2. J Biol Chem 279: 48707-48715.
31. Rosner M, Hofer K, Kubista K, Hengstschläger M. (2003). Cell size regulation by the human TSC tumor suppressor proteins depends on PI3K and FKBP38. Oncogene 22: 4786-4798.
32. Roux PP, Ballif BA, Anjum R, Gygi SP, Blenis J. (2004). Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc Natl Acad Sci USA 101: 13489-13494.
33. Shah OJ, Wang Z, Hunter T. (2004). Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol 14: 1650-1656.
34. Shaw RJ, Cantley LC. (2006). Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441: 424-430.
35. Soucek T, Hölzl G, Bernaschek G, Hengstschläger M. (1998a). A role of the tuberous sclerosis gene-2 product during neuronal differentiation. Oncogene 16: 2197-2204.
36. Soucek T, Pusch O, Wienecke R, DeClue JE, Hengstschläger M. (1997). Role of the tuberous sclerosis gene-2 product in cell cycle control. Loss of the tuberous sclerosis gene-2 induces quiescent cells to enter S phase. J Biol Chem 272: 29301-29308.
37. Soucek T, Yeung RS, Hengstschläger M. (1998b). Inactivation of the cyclin-dependent kinase inhibitor p27 upon loss of the tuberous sclerosis complex gene-2. Proc Natl Acad Sci USA 95: 15653-15658.
38. Tee AR, Fingar DC, Manning BD, Kwiatkowski DJ, Cantley LC, Blenis J. (2002). Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci USA 99: 13571-13576.
39. Wohlfart S, Sebinger D, Gruber P, Buch J, Polgar D, Krupitza G et al. (2004). FAS (CD95) mutations are rare in gastric MALT lymphoma but occur more frequently in primary gastric diffuse large B-cell lymphoma. Am J Pathol 164: 1081-1089.
40. Xiao G-H, Shoarinejad F, Jin F, Golemis EA, Yeung RS. (1997). The tuberous sclerosis 2 gene product, tuberin, functions as a Rab5 GTPase activating protein (GAP) in modulating endocytosis. J Biol Chem 272: 6097-6100.